07:00 , May 2, 2016 |  BC Week In Review  |  Company News

Enumeral Biomedical, Pieris Pharmaceuticals deal

Enumeral granted Pieris exclusive, worldwide rights to IP related to its preclinical anti- PD-1 antibody program, ENUM 388D4 , for development and commercialization of fusion proteins based on Pieris’ Anticalins platform to treat cancer. Enumeral...